Mesothelin - The novel, non-invasive in vitro biomarker to aid in the diagnosis of Mesothelioma
Mesothelioma is a rare form of cancer that is linked to exposure to asbestos. Although malignant mesothelioma remains a relatively uncommon malignancy, it continues to represent an important cause of mortality in numerous areas worldwide; eg, England, Wales, continental Europe, and Australia. Recent estimates suggest that in coming decades, as much as 1% of deaths among men in the United Kingdom currently aged 49-54 may be due to mesothelioma.1 Age standardized incidence rates for mesothelioma in men range from around 8 per 100,000 in Scotland, England, and The Netherlands; 2-4 per 100,000 in France, Italy, and Germany; and 1 per 100,000 in Spain.2 The corresponding rate for Australia is estimated to be around 6 per 100,000.3 The disease is more likely to occur in men than in women.
There are 3 classifications of mesothelioma:
Pleural — cancer in the chest cavity.
Peritoneal — cancer that starts in the abdomen. (This classification is a form that represents between 10-20% of the mesotheliomas diagnosed.)
Pericardial — cancer in the cavity around the heart. (The most rare form of mesothelioma.)
Lumipulse® G Mesothelin
Unique mono-test immunoreaction cartridges for in vitro diagnostic (IVD) use with the LUMIPULSE G System for the quantitative determination Soluble Mesothelin Related Peptides (SMRP) in human serum or plasma. The assay utilizes proven CLEIA (ChemiLuminescent Enzyme Immunoassay) technology with results that are available in 30 minutes.